Adlai Nortye Initiates Phase II Clinical Trial of Palupiprant for Locally Advanced Rectal Cancer Treatment’
Singapore, North Brunswick, NJ, and Hangzhou, China, May 22, 2024’Adlai Nortye Ltd. (NASDAQ: ANL), a clinical-stage biotechnology firm specializing in cutting-edge cancer treatments, is pleased to announce the initiation of its Phase II clinical trial for palupiprant (AN0025), a promising small molecule prostaglandin E receptor 4 (EP4) antagonist. The first patient has been successfully dosed in this trial, known as ARTEMIS (Augmenting RadioTherapy in REctal Cancer to Minimise Invasive Surgery), aimed at improving treatment outcomes for patients with locally advanced rectal cancer.
The ARTEMIS trial is a collaborative effort developed and led by the Cancer Research UK (CRUK) Clinical Trials Unit (CTU) at the University of Leeds. The trial boasts an expert clinical leadership team comprising consultant oncologists Prof. Simon Gollins and Prof. Mark Saunders. The primary focus of the trial is to evaluate the efficacy of palupiprant when combined with chemoradiotherapy and radiotherapy (total neoadjuvant therapy: TNT), aiming to enhance the standard treatment regimen for rectal cancer.
Palupiprant (AN0025) is an innovative EP4 receptor antagonist that has shown potential in preclinical studies to effectively inhibit tumor growth and metastasis. When used in combination with chemoradiotherapy and radiotherapy, it could amplify the therapeutic effects, ultimately reducing the necessity for invasive surgical procedures. This could represent a significant advancement in the treatment paradigm for rectal cancer, offering hope for improved patient outcomes and quality of life.
The initiation of the ARTEMIS trial underscores Adlai Nortye’s commitment to developing novel cancer therapies. With the collective expertise of Adlai Nortye and the University of Leeds’ CRUK Clinical Trials Unit, the trial is well-positioned to deliver valuable insights into the role of palupiprant in rectal cancer treatment. The collaboration represents a synergetic effort to bring forth innovative treatments that may one day transform the standard of care for rectal cancer patients globally.
“We are thrilled to dose the first patient in the ARTEMIS trial and are optimistic about the potential of palupiprant to improve treatment outcomes for patients with locally advanced rectal cancer,” said the CEO of Adlai Nortye. “This trial represents a crucial step in our mission to develop and deliver life-changing therapies for cancer patients worldwide.”
As the ARTEMIS trial progresses, Adlai Nortye remains dedicated to its vision of pioneering transformative cancer therapies. The successful dosing of the first patient marks only the beginning of what the company hopes will be a groundbreaking journey toward more effective and less invasive treatments for rectal cancer.
Comments